Teradyne (TER) Stock Declines While Market Improves: Some Information for Investors

Teradyne (TER) shares closed down 1.15% at $91.96, underperforming a rising market, though the stock has outperformed its sector and the S&P 500 over the past month. Ahead of its July 29, 2025 earnings report, consensus estimates project significant Q2 declines, with EPS expected to fall 37.21% to $0.54 and revenue down 11.49% to $646.05 million, though full-year revenue is anticipated to grow 3.18%. TER trades at a notable valuation premium with a Forward P/E of 29.35 and PEG ratio of 4.06, significantly above industry averages, and currently holds a Zacks Rank #3 (Hold).

Analysis

Teradyne (TER) presents a mixed investment profile characterized by recent price strength clashing with deteriorating near-term fundamentals and a rich valuation. While the stock's 7.64% gain over the past month has outpaced both its sector and the S&P 500, its recent 1.15% decline on a positive market day signals potential investor apprehension ahead of its upcoming earnings. Consensus estimates for the next quarter are notably weak, projecting a 37.21% year-over-year decline in EPS to $0.54 and an 11.49% drop in revenue. This starkly contrasts with full-year forecasts, which anticipate a modest 1.55% earnings dip but a 3.18% revenue increase, implying a significant back-half recovery is expected by analysts. This recovery narrative is critical, as TER's valuation appears demanding with a Forward P/E of 29.35 and a PEG ratio of 4.06, both substantially above industry averages of 18.94 and 1.78, respectively. The slight 0.21% upward revision in consensus EPS over the last month and a neutral Zacks #3 (Hold) rank provide little conviction against the backdrop of these challenging metrics.

Key Decisions for Investors

• Investors should be cautious of the stock's high valuation, as its Forward P/E of 29.35 and PEG ratio of 4.06 suggest the price already reflects a strong future recovery that may not materialize.
• The upcoming earnings report is a critical catalyst; focus on management's full-year guidance to determine if the anticipated second-half rebound, which underpins current full-year revenue growth estimates of 3.18%, is still on track.
• Given the conflicting signals of strong monthly performance against a poor near-term outlook and a neutral Zacks Rank #3 (Hold), it may be prudent to await the earnings disclosure before initiating or adding to positions.